A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ENERGIZE)
Phase of Trial: Phase II
Latest Information Update: 28 Nov 2018
At a glance
- Drugs Zirconium silicate (Primary) ; Glucose; Insulin
- Indications Hyperkalaemia
- Focus Therapeutic Use
- Acronyms ENERGIZE
- Sponsors AstraZeneca
- 18 Nov 2018 This trial has been Discontinued in Denmark.
- 23 Oct 2018 Planned End Date changed from 12 Dec 2018 to 26 Dec 2018.
- 23 Oct 2018 Planned primary completion date changed from 12 Dec 2018 to 26 Dec 2018.